Original title: The 2026 pulmonary embolism guideline in a regional intensive care unit: Reading the recommendations without a catheter laboratory
Prashant Maan · September 2026
A pulmonary embolism happens when a blood clot blocks blood flow in the lungs. In 2026, new medical guidelines recommended advanced treatments using thin tubes called catheters to clear these clots. The problem is that most regional intensive care units in Australia do not have the catheter labs needed to run these procedures. Researchers examined how smaller hospitals can still apply the guidelines. Care is straightforward for the lowest-risk and highest-risk patients. However, patients with intermediate-high or early high-risk clots are tricky. They might get worse, but standard clot-busting drugs carry dangerous bleeding risks. The researchers show that full-body clot-busting medication remains the only local clot-clearing option. They created a guide to help regional doctors weigh these bleeding risks and decide when to contact a major city hospital.
Imagine you have a serious blockage in a home pipe. You can pour a harsh chemical to clear it, but that might damage the pipe. Or you can call a specialist with a special tool, but they are far away. The chemical is risky but available now. In this paper, the regional ICU has only the chemical option for treating a clot in the lung, while the specialist's tool is only available at distant hospitals. The doctors must decide whether to use the risky chemical or wait for the specialist.
Patients in regional Australian intensive care units who have an intermediate-high risk pulmonary embolism face a difficult choice: they may need reperfusion but often have bleeding risks that make standard clot-busting drugs dangerous. Without on-site catheter labs, their doctors must decide whether to give systemic thrombolysis, which could cause bleeding, or transfer to a tertiary centre, which takes time. This paper offers a practical decision table to help regional clinicians navigate that trade-off, based on the latest guideline.
The management table presented has not been prospectively validated, so its effectiveness and safety are not yet proven. The paper is a reasoning guide rather than a clinical trial. It is designed for Australian regional units and may not be directly applicable elsewhere.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
The 2026 pulmonary embolism guideline in a regional intensive care unit: Reading the recommendations without a catheter laboratory — Prashant Maan — Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine — doi:10.1016/j.ccrj.2026.100218
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.